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Abstract
Background—Although cognitive deficits in patients with schizophrenia are rooted early in 
development, the impact of psychosis on the course of cognitive functioning remains unclear. In 
this study a nested case-control design was used to examine the relationship between emerging 
psychosis and the course of cognition in individuals ascertained as clinical high-risk (CHR) who 
developed psychosis during the study (CHR+T).
Method—Fifteen CHR+T subjects were administered a neurocognitive battery at baseline and 
post-psychosis onset (8.04 months, S.D. = 10.26). CHR+T subjects were matched on a case-by-
case basis on age, gender, and time to retest with a group of healthy comparison subjects (CNTL, 
n = 15) and two groups of CHR subjects that did not transition: (1) subjects matched on 
medication treatment (i.e. antipsychotics and antidepressants) at both baseline and retesting 
(Meds-matched CHR+NT, n = 15); (2) subjects unmedicated at both assessments (Meds-free CHR
+NT, n = 15).
Results—At baseline, CHR+T subjects showed large global neurocognitive and intellectual 
impairments, along with specific impairments in processing speed, verbal memory, sustained 
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attention, and executive function. These impairments persisted after psychosis onset and did not 
further deteriorate. In contrast, CHR+NT subjects demonstrated stable mild to no impairments in 
neurocognitive and intellectual performance, independent of medication treatment.
Conclusions—Cognition appears to be impaired prior to the emergence of psychotic symptoms, 
with no further deterioration associated with the onset of psychosis. Cognitive deficits represent 
trait risk markers, as opposed to state markers of disease status and may therefore serve as possible 
predictors of schizophrenia prior to the onset of the full illness.
Keywords
Clinical high risk; linear mixed-effects models; nested case-control study; neurocognition; 
prodromal; psychosis
Introduction
Cognitive deficits have long been considered core features of schizophrenia and other 
psychotic disorders (Elvevag & Goldberg, 2000; Green et al. 2004; Keefe & Harvey, 2012). 
Deficits in processing speed and verbal memory, for example, pervasively endure 
throughout the lifespan and are major contributors of the profound disability that is 
associated with the illness (Green & Harvey, 2014). However, the role of impaired cognition 
in the onset of psychosis is not yet fully understood and is an issue of central importance in 
the possible prevention of illness. A key unresolved etiological question is whether cognitive 
deficits represent long-standing traits that are part of the lifelong vulnerability to 
schizophrenia or, alternately, whether the emergence of psychotic symptoms causes a 
noticeable drop in cognitive functioning (McGlashan, 2006). Although considerable data 
suggest that impaired cognition is in fact neurodevelopmental in nature (Cornblatt et al. 
1999; Zipursky et al. 2013; Bora, 2015) with problems detectable early in life (Cannon et al. 
2000), there is a persistent view in the literature that cognition follows a neurodegenerative 
course through the progression of psychotic illness (Bilder et al. 1992; Gold, 1998), Since 
neurocognition provides a window into brain functioning, understanding the course of 
cognitive functioning in schizophrenia may provide an opportunity of reducing risk for later 
psychosis (Cornblatt et al. 2003; Lencz et al. 2006; Pukrop et al. 2007; Michel et al. 2014). 
Therefore, the goal of the current report was to prospectively examine the course of 
neurocognition before and after the transition to psychosis in a group of individuals initially 
ascertained as clinical high-risk (CHR, i.e. putative prodrome to psychosis).
Although it is well-documented that cognitive deficits are rooted early in neurodevelopment 
(Cannon et al. 2000; Fusar-Poli et al. 2012a), earlier cross-sectional studies with patients 
with first-episode psychosis (FEP) found less severe neuropsychological deficits compared 
to chronically ill patients (Schwartzman & Douglas, 1962; Bilder et al. 1992), suggesting 
that deterioration may have occurred after the onset of psychotic symptoms. The cross-
sectional design, however, makes it difficult to tease apart true progressive changes after 
illness onset, as the recruitment of chronic patients may be biased toward participants with 
poorer neurocognition (Keshavan et al. 2005). Similarly, older patients with a chronic 
course of schizophrenia are more likely to be recruited from services that provide ongoing 
treatments for poor outcomes and disability. More recent cohort studies have found evidence 
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of altered neurocognitive trajectories in individuals that developed schizophrenia relative to 
those who did not develop the schizophrenia (Reichenberg et al. 2002, 2010; Caspi et al. 
2003; Meier et al. 2014). Meier et al. (2014) for example, demonstrated a decline in 
cognitive performance in individuals who developed schizophrenia repeatedly tested from 
childhood through adulthood (at age 38) after illness onset.
While these findings suggest neurocognitive deterioration over the course of illness 
progression, determining the exact timing of the decline is relatively difficult. Cognitive 
decline could have occurred during the prodromal period, during the first episode, or after 
the onset of psychosis (Seidman et al. 2006; Bora, 2014). In addition, inconsistent 
neuropsychological test batteries over the course of a longitudinal study further complicates 
determining whether or not the onset of psychosis, per se, causes further deterioration in 
cognitive performance (Bora, 2014). Moreover, the impact of the onset and development of 
psychosis, in and of itself, on the course of cognition in the earliest stages of the illness 
remains unclear.
Looking to overcome these problems and address the specific issue of whether the onset of 
psychosis causes further deterioration in cognition, recent studies have prospectively 
followed individuals that are earlier in the course of illness and are at CHR for developing 
psychosis. These adolescents and young adults with increasing attenuated positive 
symptoms are in a critical phase of illness progression and developmental brain maturation 
processes that may contribute to the pathogenesis of the illness. To date, several CHR 
studies (Keefe et al. 2006; Wood et al. 2007; Hawkins et al. 2008; Becker et al. 2010; 
Jahshan et al. 2010; Woodberry et al. 2013) have examined the course of cognitive 
functioning in individuals transitioning to psychotic disorders (i.e. converters) during 
prospective follow-up. For example, Wood et al. (2007) found that individuals who 
progressed to full-blown psychosis showed a decline over the follow-up period on measures 
of visual memory and attentional set-shifting. Similarly, Woodberry et al. (2013) also found 
a progressive impairment in verbal memory in those who transitioned to psychosis. In 
contrast, Becker et al. (2010) reported no deterioration after the onset of psychosis, with 
large and stable impairments for converters in verbal memory and processing speed.
These inconsistencies may be related to several factors. First, many studies do not account 
for certain factors that are known to impact the neurodevelopment trajectory of the illness, 
like gender (Walder et al. 2013) and age (Glahn et al. 2013). Second, the duration of time 
between assessments could partially explain differences between those who develop 
psychosis and those who did not (Becker et al. 2010). Participants not developing psychosis 
during the study are tested at regular and pre-determined intervals (e.g. 12 and 24 months). 
In contrast, the development of psychosis and the post-psychosis neurocognitive assessment 
can occur at any time between regularly scheduled assessments resulting in different 
practice effects. Lastly, the impact of medication treatment with antipsychotics and 
antidepressants on cognition in CHR subjects who develop psychosis is unclear. This last 
issue is an important point of consideration given that previous work from our group (Bowie 
et al. 2012) found that antipsychotic treatment was associated with worse neurocognitive 
performance in high-risk subjects over a short amount of time. Furthermore, cumulative 
exposure to anti-psychotic treatment in schizophrenia may be significantly associated with 
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changes in brain structure and function over time (Fusar-Poli et al. 2013). This is 
particularly problematic in high-risk samples as true positives are treated with a higher 
proportion of antipsychotics (Cannon et al. 2008; Ruhrmann et al. 2010), further 
confounding the relationship between the onset of psychosis and neurocognition. For 
example, while Hawkins et al. (2008) found a post-psychosis decline in motor speed, 
treatment with olanzapine was initiated in the CHR subjects who developed psychosis prior 
to the post-conversion assessment making it difficult to attribute the decline to the onset of 
psychosis.
In order to determine whether the neurocognitive deficits that characterize schizophrenia are 
stable traits, present prior to the onset of psychosis, or manifest due to emergence of 
psychosis, the course of neurocognition was examined in individuals initially ascertained as 
CHR who transitioned to psychosis over the course of the prospective study (i.e. converters). 
The neurocognitive performance of the CHR converters was examined pre-psychosis (i.e. 
baseline assessment) and shortly after the onset of psychosis and compared to CHR subjects 
who did not develop psychosis and healthy control subjects. A nested case-control design 
was conducted to avoid the possible confounding effects of age, gender, time between 
assessments, and medication treatment. Based on recent meta-analytic data that FEP patients 
show no deterioration in neurocognitive performance relative to pre-morbid levels (Bora & 
Murray, 2014) we hypothesized that cognitive deficits in true positives (CHR subjects who 
developed psychosis) would be apparent prior to the onset of psychosis and would remain 
stable after post-psychosis onset with no deterioration despite the emergence of psychosis.
Method
Design
In this nested case-control study, the CHR subjects who transitioned to psychosis (CHR+T) 
were assessed before and after the onset of psychosis. CHR+T subjects were matched to two 
groups of CHR subjects who did not transition to psychosis (CHR+NT). The first group of 
CHR+NT subjects were matched for age, gender, baseline severity of positive symptoms, 
time to retest, and medication status (antipsychotic and antidepressant) at baseline and retest. 
The second group of CHR+NT subjects were matched for the same demographic and 
clinical variables, but were unmedicated at both baseline and retest. Healthy controls were 
also included to assess practice effects. The nested design allowed us to address: (1) 
cognitive changes over time in subjects who developed psychosis (CHR+T); and (2) practice 
effects of matched CHR+NT subjects, unrelated to psychosis, medication, age, gender, and 
time to retest.
Participants
This paper reports retest data for participants recruited during Phase 1 (2000–2006) and 
Phase 2 (2006–2012) of the Recognition and Prevention (RAP) Program, an ongoing 
longitudinal investigation initiated in 1998 and funded by the National Institute of Mental 
Health in 2000. Patient referrals were made to the RAP Program by affiliated outpatient and 
inpatient psychiatry departments, local mental health providers, school psychologists or 
counselors, or were self-referred. All procedures were approved by the Institutional Review 
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Board at the North Shore-LIJ Health System. Written informed consent (with assent from 
participants aged <18 years) was obtained from all participants.
Forty-five participants meeting criteria for Clinical High-Risk, Positive (CHR+) derived 
from the Scale of Prodromal Symptoms (SOPS; Miller et al. 1999, 2002, 2003) were 
included in this nested sub-sample. Inclusion criteria were based on the presence of one or 
more moderate, moderately severe, or severe (scores of 3, 4, or 5) SOPS rated attenuated 
positive symptoms (scale 0–6). A score of 6 (severe and psychotic) on any item was an 
exclusion factor for the CHR group. In this paper, subjects in the CHR+ group are broadly 
comparable to those considered ‘prodromal’ in most other studies in North America and 
internationally (Correll et al. 2010).
Recruitment in Phase 1 and Phase 2 yielded a total of 240 CHR+ participants. The current 
nested sub-sample included 15 CHR+T subjects out of a total of 23 CHR+T subjects who 
developed a psychotic disorder. Eight CHR+T subjects were excluded for not having both a 
pre- and post-psychosis onset neuropsychological assessment. Matches for the CHR+T 
subjects were selected from a total pool of 217 CHR+NT subjects. Of the 217 CHR+NT 
subjects, 188 had a baseline and at least one follow-up visit. Forty CHR+NT subjects were 
unmedicated at both testing points and a total of 148 were medicated at either the baseline or 
retest assessment. The sample selection process is outlined in Supplementary Fig. S1.
The 15 CHR+T subjects in the current study were tested at both time 1 (baseline, before 
psychosis) and time 2 (retest, post-psychosis). Mean time to conversion was 12.34 months 
(S.D. = 16.06, median = 8.31). The mean time between conversion and the post-conversion 
retest was 8.14 months (S.D. = 10.19, median = 3.55). Diagnoses at the last follow-up 
evaluation included: schizophrenia (n = 6), psychosis not otherwise specified (n = 5), bipolar 
I disorder, most recent episode manic, severe with psychosis (n = 3), delusional disorder, 
persecutory type (n = 1).
CHR+T subjects were matched on a case-by-case (1:1 ratio) with two groups of CHR+NT 
subjects: (1) Meds-matched CHR+NT subjects (n = 15) matched on medication treatment 
(i.e. antipsychotics, anti-depressants) at both baseline and retesting; (2) Meds-free CHR+NT 
subjects (n = 15) unmedicated at both assessments. The CHR+T subjects were also matched 
in a 1:1 ratio with healthy comparison subjects (CNTL; n = 15). All four subject groups 
were therefore matched on gender, age (±1-year window), and time to retest (±4-month 
window). All subjects on medication at testing were receiving stable doses for at least 2 
weeks prior to the assessment.
CNTLs were recruited through announcements in local newspapers and within the medical 
center. Inclusion criteria required participants to be between the ages of 12 and 22 years. 
Exclusion criteria for all participants included: (1) schizophrenia-spectrum diagnosis; (2) 
non-English speaking; (3) a medical or neurological disorder; (3) estimated IQ < 70. Healthy 
controls with a first-degree relative with a diagnosed Axis I psychotic disorder were also 
excluded.
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Baseline clinical assessment
Axis I diagnoses were assessed by the Schedule for Affective Disorders and Schizophrenia 
for School-Age Children, Epidemiologic Version (K-SADS-E; Orvaschel & Puig-Antich, 
1994). Prodromal symptoms were assessed by the Structured Interview for Prodromal 
Syndromes (SIPS) and the companion SOPS (Miller et al. 1999). Conversion to psychosis 
was defined as the presence of a psychotic level positive symptom (score of 6 on the SOPS). 
The K-SADS-E was used to confirm diagnoses in those participants whose symptoms 
developed into full psychotic disorders. Social and role functioning was assessed using the 
GF: Social and GF:Role scales (Cornblatt et al. 2007). The GF:Social scale assesses peer 
relationships, peer conflict, age-appropriate intimate relationships, and involvement with 
family members. The GF:Role scale rates performance and amount of support needed in 
one’s specific role (i.e. school, work).
Baseline neurocognitive assessment
Patients were administered a comprehensive battery of tests that took approximately 3.5 h to 
complete at study entry. Testers were at the master’s level or above and trained in the 
administration and scoring of all tests. Estimated full-scale IQ scores were derived from the 
Vocabulary and Block Design subscales of the Wechsler Intelligence Scale for Children, 3rd 
edition (WISC-III; Wechsler, 1991) for subjects aged <16 years and from the same 
subscales of the Wechsler Adult Intelligence Scale, Revised (WAIS-R; Wechsler, 1981) for 
subjects aged ≥16 years.
In addition to the intelligence tests, the baseline and retest batteries included 
neuropsychological tests that assessed six cognitive domains (see Table 1): processing 
speed, verbal memory, executive function, working memory, sustained attention, and 
language. Domain construction was based on: (1) rational criteria derived from previous 
findings in patients with schizophrenia that demonstrated separable neurocognitive factors 
(Green et al. 2004) and; (2) previous work with subjects at CHR that demonstrated the 
content validity of the domains (see Seidman et al. 2010; Carrión et al. 2011, 2013 for more 
details). Prior to neurocognitive domain construction, raw test scores were log-transformed 
to reduce skewness and improve the distribution. Extreme values (±3.5 S.D.) were 
Winsorized to reduce the impact of outliers.(Dixon & Tukey, 1968) Test scores were then 
transformed into standard Z scores using the age-stratified means and S.D.s of a larger group 
of CNTLs (n = 114) to control for age-related change in cognitive performance. When 
applicable, tests were reverse-scored so that lower scores reflected worse performance. 
Domain scores were computed by averaging each subject’s Z scores on tests assessing the 
same neurocognitive domain. Z scores for each domain were then re-standardized using the 
mean and S.D. of the domain scores of the healthy comparison group. A composite of global 
neurocognitive performance was calculated by averaging the neurocognitive domains.
Statistical analyses
All analyses were conducted using SPSS 16.0 (SPSS Inc., USA). Comparisons of 
demographic and clinical characteristics were performed with Student’s t tests for 
continuous variables, Pearson’s χ2 or Fisher’s exact tests for categorical variables, and 
Kolmogorov–Smirnov Z for one ordinal variable (two-tailed, p < 0.05). Linear mixed-effects 
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models for repeated measures were used to compare the neurocognitive performance of the 
four subjects groups, as well as the change in performance from baseline to retest. Linear 
mixed effect modeling enabled the use of all available measurements and is robust in the 
presence of unbalanced designs (i.e. missing observations, inconsistent time intervals) and 
non-independent correlated data, providing unbiased estimates of covariance parameters 
(Verbeke & Molenberghs, 2000; Mallinckrodt et al. 2001; Gueorguieva & Krystal, 2004; 
McCulloch et al. 2008). Performance on each neurocognitive test was used as the primary 
dependent variable. Fixed effects were group (CHR+T, Meds-matched CHR+NT, Meds-free 
CHR+NT, and CNTLs) and time as (baseline and retest) and the interaction between group 
and time. The subjects were entered as a random effect. Restricted maximum-likelihood 
estimation and Type III tests of fixed effects were used, with a heterogeneous autoregressive 
covariance structure. Post-hoc pairwise comparisons were performed with Bonferroni 
corrections. Cohen’s d was calculated as the mean difference from the mixed model divided 
by the pooled standard deviation [d = (V2 – V1)/σ pooled] and can be interpreted using the 
following categories (Cohen, 1988): small = 0.20, medium = 0.50, large = 0.80. A main 
effect of time along with a group × time interaction would support evidence of a decline 
specific to the converters. Failing to find worsening in neurocognitive performance for the 
converters after the onset of psychosis, along with a significant difference between the four 
groups would suggest a pre-existing cognitive impairment for those who go on to develop a 
full-blown psychotic disorder. The linear mixed-effects models were also used to examine 
changes in clinical symptoms (SOPS total positive, negative, disorganized, and general 
symptom severity levels) from baseline to retest. Partial correlations (adjusted for group 
status) were conducted to examine the relationships between changes in neurocognitive 
performance and clinical symptoms over the follow-up period, with the alpha level adjusted 
using a Bonferroni correction for the number of tests in this analysis.
Results
Demographic and clinical characteristics
Table 2 summarizes baseline demographic and clinical characteristics for the CHR+T 
subjects along with the two groups of CHR+NT subjects and CNTLs. The four groups were 
well-matched, with no differences in baseline age, education level, gender ratio, handedness, 
race, ethnicity, and time to the retest assessment. The CNTL group had significantly better 
functioning as seen on the GAF, GF:Social and GF:Role compared to all three CHR groups, 
while the three CHR groups had comparable levels of functioning at baseline. The CHR+T 
group was retested on average 8.04 months (S.D. = 10.26) after the onset of psychosis.
Medication treatment at baseline and retest in the CHR+T and Meds-matched CHR+NT 
groups were comparable. For both groups at the baseline and retest assessment, 11 out of the 
15 subjects (73%) were taking medication. At baseline, five (33.3%) subjects were 
prescribed atypical antipsychotics and six (40.0%) anti-depressants. At the retest/post-
psychosis assessment, six (40.0%) subjects were prescribed atypical anti-psychotics and five 
antidepressants (33.3%).
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Changes in clinical symptoms
At baseline, CNTLs were significantly different from all three CHR groups, with lower 
SOPS positive, negative, disorganized, and general symptom levels. The three CHR groups 
had comparable positive and general symptom levels; however, CHR+T subjects showed 
significantly worse negative and disorganized symptoms (see Table 2).
As shown in Table 3, the linear mixed-models for repeated measures found significant group 
differences for all four SOPS symptom scales (all p < 0.001). There were also differential 
changes across time in symptom levels, as reflected by significant interactions between visit 
and group (see Table 3). The two groups of CHR+NT subjects showed substantial 
improvements over time and showed less severe symptoms at retest relative to baseline 
assessment. On the other hand, CHR+T subjects showed consistent SOPS symptom levels 
over time, with a worsening in positive symptom levels at retest. Post-hoc comparisons 
showed that compared to the healthy controls, CHR subjects showed consistently higher 
levels of SOPS positive, negative, disorganized, and general symptoms. The Meds-free CHR
+NT and Meds-matched CHR+NT groups had comparable SOPS symptom levels on all four 
subscales; however, the CHR+T subjects had higher levels of SOPS positive, negative, 
disorganized, and general symptoms compared to the two non-converter groups.
Relationship between changes in clinical symptoms and neurocognitive performance
Partial correlations between changes in clinical symptoms and neurocognitive performance 
over time indicated that increases in positive symptom severity levels were related to 
improvements in processing speed, sustained attention, working memory, and global 
cognition (see Supplementary Table S1). Similar relationships were seen also seen for 
working memory and negative symptoms as well as with global cognition and disorganized 
symptoms, suggesting that increases in symptom severity over the short follow-up period 
did not translate into declines in neurocognition. However, these effects did not withstand 
correction for multiple comparisons.
Neurocognitive performance
As shown in Fig. 1, each group demonstrated stable neurocognitive and intellectual 
performance from baseline to retest. However, compared to the healthy controls and CHR 
subjects that did not transition to psychosis, CHR+T subjects showed a consistent 
impairment in global neurocognitive and intellectual performance (see Fig. 1a, b) from 
baseline (before psychosis) to retest (after psychosis).
Estimated marginal means of IQ estimates and each neurocognitive domain derived from the 
linear mixed-models are shown in Table 4. Significant group effects were found for all the 
neurocognitive domains, including processing speed, verbal memory, executive function, 
sustained attention, working memory, and language. Post-hoc pairwise comparisons 
demonstrated that the CHR+T group had significantly lower global neurocognitive and 
intellectual scores, as well as lower performance on all six neurocognitive domains 
compared to CNTLs. The CHR+T group also had worse performance compared to the 
Meds-free CHR+NT group on every measure, except executive function and language. The 
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two non-converter groups demonstrated similar performance, without significant 
differences.
All subject groups demonstrated similar and small improvements (i.e. practice effects) in 
performance in many of the domains, with only significant improvements in sustained 
attention (p < 0.01) and processing speed (p = 0.03). Trend level improvements were also 
seen for the global neurocognitive composite (p = 0.11). Notably, group × visit interactions 
were not significant for any domain (see Table 3). Table 5 shows effect size (Cohen’s d) 
estimates for changes in intellectual and neurocognitive performance from baseline to retest 
for all four subject groups. CHR+T subjects showed similar, small effect sizes compared to 
the healthy controls and other CHR+NT comparison groups. One exception was in the 
processing speed and attention domains, with healthy controls and Meds-free CHR+NT 
subjects showing moderate to large improvements, while CHR+T and Meds-matched CHR
+NT groups showing smaller improvements over time (see Table 5).
Discussion
In order to understand the temporal and mechanistic nature of cognitive change following 
the onset of psychosis, we prospectively assessed the neurocognitive performance of a group 
of clinically at-risk adolescents and young adults before and on average 8 months after the 
emergence of full-blown psychosis. True positives, CHR subjects who developed psychosis 
after the baseline testing, showed large neurocognitive and intellectual impairments at 
baseline, prior to the onset of psychosis, compared to CHR subjects who did not transition to 
psychosis. These impairments persisted over the course of the short follow-up period, with 
no further deterioration seen after the onset of psychosis. Moreover, the same seems to be 
true for antipsychotic and antidepressant treatment, at least in the short-term. On the other 
hand, false-positives, subjects ascertained as CHR but who did not transition over the 
follow-up period, demonstrated mild to no impairments in neurocognitive and intellectual 
performance independent of medication treatment, suggesting that cognitive impairment 
during the prodrome is related to the underlying vulnerability to illness, consistent with the 
neurodevelopmental model (Weinberger, 1987). Taken together, our results indicate that 
cognition is impaired prior to the onset of psychosis and that the onset of psychosis, in and 
of itself, does not have a detrimental or ‘neurotoxic’ effect on the course of neurocognition. 
Thus, cognitive deficits represent trait risk markers, as opposed to state markers of disease 
status and may serve as possible predictors of schizophrenia prior to the onset of the full 
illness.
At baseline, individuals at CHR who later converted to psychosis showed a global 
neurocognitive impairment that mirrored performance levels seen in patients with FEP 
(Addington & Addington, 2002; Gonzalez-Blanch et al. 2007). True prodromal subjects 
showed a deficit in overall neurocognitive performance that was approximately 1.5 S.D.s 
below that of the healthy controls. These impairments persisted after the onset of full-blown 
psychosis and did not decline further. Rather, converters to psychosis actually demonstrated 
small improvements that were most likely due to practice effects over the follow-up period 
that were highly comparable to those seen in both non-converter groups. In addition to a 
global neurocognitive impairment, converters also demonstrated stable intellectual deficits 
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that were significantly lower than levels seen in the healthy comparison and matched non-
converter groups. In fact, the level of estimated IQ levels seen in the converter group is in 
line with a large body of evidence from cohort studies that have associated lower intellectual 
performance with a higher risk for developing schizophrenia (David et al. 1997).
Converters also showed large impairments of ≥1.5 S.D.s below healthy control levels in 
specific areas of neurocognition, including sustained attention, verbal memory, processing 
speed, and executive function. Deficits in these domains have been well-documented at 
different stages of psychotic illness and have been described as among the core cognitive 
deficits in schizophrenia (Green et al. 2004). Performance in sustained visual attention as 
measured by the CPT-IP has been found to be heritable, reliable, and stable (independent of 
clinical state), representing a promising endophenotype for molecular genetics research in 
schizophrenia (Cornblatt & Malhotra, 2001). Impairments in verbal learning and memory 
have been shown to make an independent contribution to the prediction of psychosis in CHR 
subjects (Lencz et al. 2006). Becker et al. (2010) also found stable deficits in verbal memory 
as assessed by the CVLT (Trials 1–5, free recall total correct) in CHR subjects before and 
after the onset of psychosis compared to healthy controls. Moreover, in a meta-analytic 
review of neurocognitive deficits in first-episode psychosis, Mesholam-Gately et al. (2009) 
found that performance on measures of verbal memory, the CVLT included, were among the 
poorest compared to healthy levels. Finally, processing speed plays a central role in a variety 
of high-order cognitive abilities such as language and reading as well as functional outcomes 
in the earliest phases of the illness (Carrión et al. 2011; Meyer et al. 2014). Moreover, due to 
the varying task demands (e.g. flexibility, cognitive control, visual scanning, and motor 
abilities) used in processing speed measures, deficits in this domain are mostly likely 
reflective of dysfunction in spatially distributed and interconnected brain regions that are 
linked to the underlying pathophysiology of the illness (Dickinson et al. 2007).
Indeed, these domain-specific deficits most likely reflect a dysfunction of complex 
integrative neural systems that subserve the neuropsychological measures. Our findings are 
consistent with mounting evidence of the presence of neurofunctional (Fusar-Poli et al. 
2007) and neuroanatomical (Fusar-Poli et al. 2012b) abnormalities prior to the onset of 
psychosis in subjects at CHR. Abnormal functional connectivity has been found within brain 
networks that underlie domain-specific performance in working memory, executive 
function, and processing speed tasks, for example, that include the dorsolateral prefrontal 
cortex and anterior cingulate cortex, along with hippocampus and subcortical regions. Future 
prospective cohorts with larger CHR converter groups (e.g. North American Prodrome 
Longitudinal Study), can examine the relationship between neurocognition along the 
pathway towards psychosis and changes in brain morphology that have been documented in 
CHR individuals (Pantelis et al. 2003; Cannon et al. 2015).
Limitations
Our findings should be interpreted in light of the following potential limitations. First, our 
data cannot rule out cognitive deterioration at other periods along the trajectory of the 
disease. The current report only addresses one critical window on the pathway to illness, the 
prodrome to shortly after post-psychosis. Decline may occur in childhood or closer to onset 
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of the prodrome (Harvey, 2014). Moreover, the relatively short time frame (8 months) 
between transition and retest does not rule out further deterioration in the long-term course 
of the established illness. Cognitive deterioration may occur years later, possibly 
exacerbated by prolonged medication treatment and repeated hospitalizations. However, 
recent meta-analyses have not found support for deterioration in older patients with a 
chronic course of schizophrenia (Szöke et al. 2008).
Second, it is possible that cognitive functions other than those studied here (e.g. visual 
memory) do not deteriorate until psychosis manifests, or become more impaired as the 
illness becomes more chronic. Third, the current study only used a combination of the block 
design and vocabulary sub-tests to estimate a full-scale IQ. This combination of a verbal and 
performance measure did, however, demonstrate excellent stability across time in all four 
comparison groups.
Finally, our ability to detect subtle differences between the groups and to relate individual 
differences in cognitive course to clinical outcome may have been hindered by the small 
sample of converters. However, the size of the transitioned group is in line with previous 
studies that have retested CHR subjects before and after the onset of psychosis (e.g. n = 17, 
Becker et al. 2010; n = 16, Wood et al. 2007; n = 10, Woodberry et al. 2013). Furthermore, 
the neurocognitive effect sizes from baseline to retest were consistent for each group. 
Despite the small sample size, the effect size of cognitive change over time was consistent 
across groups, with almost all subjects groups showing small improvements (85% of the 
results) in performance over time. These sample sizes are most likely due to the difficulty in 
obtaining repeated neurocognitive assessments on individuals who transition to psychosis 
during the course of a prospective study, especially after the onset of psychosis. 
Nevertheless, this limitation should not necessarily diminish the interpretation of the 
primary result, that is, converters as a group did not show decline in neurocognitive function 
after the onset of psychosis.
In addition, our study design has a number of strengths compared with previous research. 
Converters were well-matched to three separate comparison groups on a number of variables 
known to influence cognitive performance. Confounding by age, gender, baseline positive 
symptoms, medication at testing, and time to retest are unlikely to explain the key findings. 
The nested-case control design also minimizes selection bias as cases and controls were 
sampled from the same cohort ensuring the comparability of the groups.
In summary, the current study does not provide evidence of cognitive deterioration shortly 
after the emergence of full-blown psychosis. On the contrary, large cognitive deficits are 
apparent in true positives pre- and post-psychosis onset, with no signs of decline, and 
therefore appear to be stage-invariant vulnerability traits. Our findings provide further 
support for the important role of cognition in the neurodevelopmental processes leading to 
psychotic illness that may ultimately serve as a target for preventive intervention.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
(a) Global neurocognitive and (b) intellectual performance (±S.E.) at baseline and retest 
assessment (post-conversion or matched testing based on duration from baseline) for all four 
groups. Global neurocognitive performance was calculated by averaging the six 
neurocognitive domains.
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Table 1
Neurocognitive domains, individual tests, and dependent measures
Verbal memory
California Verbal Learning Test (CVLT)
 Total for trials 1–5 Words recalled in trials 1–5
 Long delay free recall Recognition errors
Working memory
 Wechsler Intelligence Scale for Children – III/Wechsler
 Adult Intelligence Scale – R (WISC-III/WAIS-R)
 Digit span forward and backward Digit sequences recalled
 Letter-number span Number of correct trials
Executive function
Wisconsin Card Sorting Test (WSCT), version 2
 Perseverative errors Percentage of perseverative errors;
 Categories completed Number of correctly completed categories
 Conceptual level responses Number of consecutive correct responses in ≥3 runs
Controlled Oral Word Association Test (COWAT) Words produced in 1 min
Sustained attention
Continuous Performance Test – Identical Pairs (CPT-IP) d′ (for all stimulus sets)
 2, 3, and 4 digits
Processing speed
 Trails Making Test, Part A and B Time to complete trails
 WISC-III/WAIS-R digit symbol coding Symbols accurately coded in 2 min
 Animal naming test
Language
 Wide Range Achievement Test – III (WRAT-III) Reading Total score for words read correctly
 WAIS-R/WISC-III vocabulary Number of words orally defined
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Table 5
Effect sizes (Cohen’s da) of neurocognitive change over time for the four subject groups
Variable CNTL Meds-free CHR+NT Meds-matched CHR+NT CHR+T
IQ 0.03 0.02 0.10 0.04
Global neurocognitive composite 0.09 0.30 0.13 0.15
Verbal memory 0.32 0.00 0.45 0.37
Processing speed 0.22 0.66 0.06 0.07
Sustained attention 0.50 0.35 0.05 0.07
Executive function 0.16 0.15 0.17 0.30
Working memory 0.21 0.04 0.03 0.16
Language 0.10 0.11 0.22 0.02
CNTL, Healthy comparison subjects; CHR+NT, CHR+ subjects who did not transition to psychosis; CHR+T, CHR+ subjects who did transition to 
psychosis.
aCohen (1988) recommended the following categories for interpreting effect sizes: small = 0.2, medium = 0.5, and large = 0.8.
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